CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma.
CK1α
RUNX2
bone marrow microenvironment
multiple myeloma
target therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Aug 2022
29 Aug 2022
Historique:
received:
06
07
2022
revised:
10
08
2022
accepted:
22
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Multiple myeloma (MM) is a malignant plasma cell (PC) neoplasm, which also displays pathological bone involvement. Clonal expansion of MM cells in the bone marrow causes a perturbation of bone homeostasis that culminates in MM-associated bone disease (MMABD). We previously demonstrated that the S/T kinase CK1α sustains MM cell survival through the activation of AKT and β-catenin signaling. CK1α is a negative regulator of the Wnt/β-catenin cascade, the activation of which promotes osteogenesis by directly stimulating the expression of
Identifiants
pubmed: 36077711
pii: cancers14174173
doi: 10.3390/cancers14174173
pmc: PMC9454895
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero dell' Istruzione, Università e Ricerca
ID : PRIN (Progetti di rilevante interesse nazionale)-MIUR Prot. 2017ZXT5WR
Références
Blood. 2014 May 15;123(20):3128-38
pubmed: 24569262
Int J Mol Sci. 2019 Apr 04;20(7):
pubmed: 30987410
J Clin Med. 2020 Sep 04;9(9):
pubmed: 32899714
Leukemia. 2015 Feb;29(2):474-82
pubmed: 24962017
J Cell Biochem. 2008 May 15;104(2):568-79
pubmed: 18186078
Cell Death Differ. 2017 Dec;24(12):2022-2031
pubmed: 28777372
Blood. 2015 Mar 19;125(12):1870-6
pubmed: 25628468
Leukemia. 2013 Aug;27(8):1715-21
pubmed: 23417027
Br J Haematol. 2003 Mar;120(5):846-9
pubmed: 12614220
Leuk Res. 2020 Mar 9;92:106340
pubmed: 32182487
Cell. 1997 May 30;89(5):747-54
pubmed: 9182762
Exp Hematol. 2013 Apr;41(4):387-97.e1
pubmed: 23178378
Hormones (Athens). 2007 Oct-Dec;6(4):279-94
pubmed: 18055419
J Cell Physiol. 2000 Sep;184(3):341-50
pubmed: 10911365
Nat Rev Cancer. 2007 Aug;7(8):585-98
pubmed: 17646864
J Biol Chem. 2005 Sep 30;280(39):33132-40
pubmed: 16043491
Oncogene. 2020 Jan;39(1):176-186
pubmed: 31462704
Int J Mol Sci. 2020 Aug 18;21(16):
pubmed: 32824859
BMC Cancer. 2010 Oct 04;10:526
pubmed: 20920357
Cancer Cell. 2014 Oct 13;26(4):509-20
pubmed: 25242043
Exp Hematol. 2014 Jul;42(7):516-25
pubmed: 24704163
Int J Oncol. 2008 Jul;33(1):129-36
pubmed: 18575758
Development. 2006 Aug;133(16):3231-44
pubmed: 16854976
Int J Mol Sci. 2020 Jul 22;21(15):
pubmed: 32707894
Int J Mol Sci. 2021 Mar 25;22(7):
pubmed: 33806209
Blood. 2005 Oct 1;106(7):2472-83
pubmed: 15933061
Exp Hematol. 2012 Oct;40(10):867-76
pubmed: 22705469
Am J Blood Res. 2014 Dec 15;4(2):73-85
pubmed: 25755907
Cancers (Basel). 2021 Jan 09;13(2):
pubmed: 33435306
PLoS One. 2013 Sep 27;8(9):e75280
pubmed: 24086494
Eur Cell Mater. 2014 Oct 23;28:269-86
pubmed: 25340806
Blood. 1995 Feb 15;85(4):997-1005
pubmed: 7849321
Acta Reumatol Port. 2007 Apr-Jun;32(2):103-10
pubmed: 17572649
Blood. 2015 Jun 4;125(23):3598-608
pubmed: 25862559
Blood. 2002 Dec 15;100(13):4615-21
pubmed: 12393684
Cell Death Discov. 2019 May 21;5:98
pubmed: 31123604
Cold Spring Harb Perspect Med. 2018 Aug 1;8(8):
pubmed: 29229668
Oncotarget. 2017 May 23;8(32):53053-53067
pubmed: 28881793
Leukemia. 2008 Oct;22(10):1925-32
pubmed: 18596740
J Biol Chem. 1995 Dec 29;270(52):30973-9
pubmed: 8537354
Endocrinology. 2007 Nov;148(11):5323-30
pubmed: 17717053
Nat Med. 2013 Feb;19(2):179-92
pubmed: 23389618
Cell Mol Life Sci. 2010 Apr;67(7):1105-18
pubmed: 20041275
Mol Cells. 2020 Feb 29;43(2):188-197
pubmed: 32041394
Bioessays. 1995 Jun;17(6):509-18
pubmed: 7575492
Int J Mol Sci. 2021 Feb 27;22(5):
pubmed: 33673409
Leukemia. 2005 Dec;19(12):2166-76
pubmed: 16208410
PLoS One. 2021 Nov 18;16(11):e0249894
pubmed: 34793446
Cell Commun Signal. 2018 May 24;16(1):23
pubmed: 29793495
Int J Mol Sci. 2020 Nov 27;21(23):
pubmed: 33261128
J Biol Chem. 2002 Jun 14;277(24):21657-65
pubmed: 11940574
Front Oncol. 2021 Oct 14;11:733848
pubmed: 34722279
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178
Int J Mol Sci. 2021 Apr 02;22(7):
pubmed: 33918307
Leukemia. 2014 Oct;28(10):2094-7
pubmed: 24897506
Mol Cancer. 2015 Jul 25;14:137
pubmed: 26204939
Am J Pathol. 2016 Jun;186(6):1598-609
pubmed: 27083516
Curr Osteoporos Rep. 2017 Oct;15(5):483-498
pubmed: 28861842
Acta Med Acad. 2019 Apr;48(1):57-67
pubmed: 31264433
Lancet Oncol. 2020 Feb;21(2):207-221
pubmed: 31859245
Semin Oncol Nurs. 2017 Aug;33(3):225-236
pubmed: 28688533
Mol Cell Biol. 2002 Sep;22(17):6222-33
pubmed: 12167715
Curr Hematol Malig Rep. 2017 Apr;12(2):109-118
pubmed: 28243849
Exp Hematol. 2009 Aug;37(8):879-86
pubmed: 19446662
J Bone Miner Res. 2006 Jul;21(7):1034-44
pubmed: 16813524
Oncotarget. 2017 Feb 28;8(9):14604-14619
pubmed: 28099937
J Cell Biol. 2006 Mar 13;172(6):909-21
pubmed: 16533949
Blood. 2015 Nov 19;126(21):2366-9
pubmed: 26438514
J Biol Chem. 2007 May 11;282(19):14515-24
pubmed: 17351296
J Hematol Oncol. 2020 Dec 4;13(1):165
pubmed: 33276800